The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT-EHA CAR-T 2019 | CAR T-cell therapy: AML adverse events and optimization
Elizabeth Budde, MD, PhD City of Hope National Medical Center, Duarte, CA, discusses the toxicities associated with CAR T-cell therapy in the treatment of acute myeloid leukemia and what optimization is needed in the manufacuring of CAR T-cell products. Dr Budde was speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
